Posts
Roots Analysis has done a detailed study on “AI-based Digital Pathology Market, 2022-2035”, covering key aspects of the market’s evolution and identifying potential future growth opportunities.   Key Market Insights Presently, close to 80 players offering AI-based digital pathology services are available in the healthcare market which are located across the globe In order to tap into the lucrative opportunity associated with AI-based digital pathology, various investment firms have invested over USD 1.7 billion in AI-based digital pathology market space, during the period 2016-2022 The estimated global demand for AI-based digital pathology is expected to grow at a CAGR of 9,4%, during 2022-2035  The projected future opportunity for companies engaged in this field is expected to be well distributed across different types of neural networks, types of assay, end-users, areas of applications, target disease indications, and key geographical regions   Table of Contents   1.         PREFACE 1.1.      Chapter Overview 1.2.      Market Segmentations 1.3.      Research Methodology 1.4.      Key Questions Answered 1.5.      Chapter Outlines   2.         EXECUTIVE SUMMARY   3.         INTRODUCTION 3.1.      Chapter Overview 3.2.      Artificial Intelligence in Digital Pathology 3.3.       Workflow of AI-based Digital Pathology 3.4.       Applications of AI-based Digital Pathology Solutions 3.5.      Regulatory Requirements Focused on AI-based Digital Pathology: 3.6.      Challenges Associated with the Use of AI in Digital Pathology 3.7.      Future Perspectives   4.         AI-BASED DIGITAL PATHOLOGY: MARKET LANDSCAPE 4.1.      Chapter Overview 4.2.      AI-based Digital Pathology Providers: Developers Landscape 4.3.      AI-based Digital Pathology Providers: Market Landscape   5.         AI-BASED DIGITAL PATHOLOGY MARKET: KEY INSIGHTS 5.1.      Chapter Overview   6.         COMPANY PROFILES 6.1.      Chapter Overview 6.2.      PathAI 6.2.1.   Company Overview 6.2.2.   Recent Developments and Future Outlook 6.3.      Paige 6.4.      Akoya Biosciences 6.5.      PROSCIA 6.6.      Visiopharm 6.7.      Roche Tissue Diagnostics 6.8.      Aiforia Technologies 6.9.      Indica Labs 6.10.    Ibex Medical Analytics   7.         COMPANY COMPETITIVENESS ANALYSIS 7.1.      Chapter Overview 7.2.      Assumptions and Key Parameters 7.3.      Methodology 7.4.      Benchmarking of Portfolio Strength               7.5.      Benchmarking of Funding Strength 7.6.      Company Competitiveness Analysis: Small Players 7.7.      Company Competitiveness Analysis: Mid-sized Players 7.8.      Company Competitiveness Analysis: Large Players                         8.         FUNDING AND INVESTMENTS 8.1.      Chapter Overview 8.2.      Types of Funding 8.3.      AI-based Digital Pathology: List of Funding and Investments 8.4.      Concluding Remarks   9.         DEMAND ANALYSIS 9.1.      Chapter Overview 9.2.      Scope and Methodology 9.3.      Global Demand for AI-based Digital Pathology, 2022-2035 9.4.      Demand for AI-based Digital Pathology: Analysis by Geography 9.5.      Demand for AI-based Digital Pathology: Analysis by Type of End-user 9.6.      Concluding Remarks   10.       MARKET SIZING AND OPPORTUNITY ANALYSIS 10.1.    Chapter Overview 10.2.    Forecast Methodology and Key Assumptions 10.3.    Global AI-based Digital Pathology Market, 2022-2035 10.4.    AI-based Digital Pathology Market: Analysis by Type of Neural Network, 2022 and 2035 10.5.    AI-based Digital Pathology Market: Analysis by Type of Assay, 2022 and 2035 10.6.    AI-based Digital Pathology Market: Analysis by Type of End-user, 2022 and 2035 10.7.    AI-based Digital Pathology Market: Analysis by Area of Application, 2022 and 2035 10.8.    AI-based Digital Pathology Market: Analysis by Target Disease Indication, 2022 and 2035 10.9.    AI-based Digital Pathology Market: Analysis by Key Geographies, 2022 and 2035   11.       CONCLUDING REMARKS   12.       EXECUTIVE INSIGHTS 12.1.    Chapter Overview 12.2.    aetherAI 12.3.    CTL Clinitech Lab 12.4.    Huron Digital Pathology 12.5.    Mindpeak 12.6.    Pramana   13.       APPENDIX 1: TABULATED DATA   14.       APPENDIX II: LIST OF COMPANIES AND ORGANIZATION     To view more details on this report, click on the link https://www.rootsanalysis.com/reports/ai-based-digital-pathology-market.html Learn from experts:  do you know about these emerging industry trends? TIL Therapies: A New Paradigm in Cancer Treatment Viral Clearance and Viral Testing Services   About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.   Learn more about Roots Analysis consulting services:  Roots Analysis Consulting - the preferred research partner for global firms   Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com    
The “Global Bioreactors and Fermenters Market, 2023-2035” report features an extensive study of the current market landscape and the likely future potential of the global bioreactors and fermenters market, over the next 12 years.     Key Inclusions An executive summary of the insights captured during our research, offering a high-level view on the current state of the global bioreactors and fermenters market and its likely evolution in the mid-long term. A general introduction to bioreactors and fermenters, along with details related to the components of a bioreactor. Additionally, the chapter presents information on different types of bioreactors based on type of bioprocess and mode of action. Further, it concludes with a discussion on applications of bioreactors and future perspectives in this domain. A detailed assessment of the overall market landscape of companies manufacturing bioreactors and fermenters, based on several relevant parameters, such as year of establishment, company size (in terms of number of employees), region of headquarters, geographical reach (North America, Europe, Asia-Pacific and Rest of the World), type of product (bioreactors and fermenters), bioreactor and fermenter capacity (micro-mini, small-scale, bench-scale, lab-scale, pilot-scale and large-scale), scale of operation of bioreactors and fermenters (preclinical, clinical and commercial), scalability of bioreactors and fermenters, type of bioprocess (batch, fed-batch and continuous), type of cell culture (2D cell culture, 3D cell culture and 4D cell culture), mode of operation of bioreactors and fermenters (manual, semi-automatic and automatic) and end users (academic institutes and research laboratories, biopharmaceutical and pharmaceutical industries, contract manufacturing organizations, and contract research organizations). A detailed competitiveness analysis of bioreactor manufacturers and fermenter manufacturers based on manufacturer strength (in terms of number of years since the company was established and company size) and product portfolio strength (geographical reach, type of bioreactor or fermenter, bioreactor and fermenter capacity, type of bioprocess, scale of operation of bioreactors and fermenters, scalability of bioreactors and fermenters, mode of operation of bioreactors and fermenters, type of product, end user, and type of cell culture). Elaborate profiles of key players manufacturing bioreactors and fermenters (shortlisted based on their bioreactor and fermenter manufacturing capabilities); each profile includes a brief overview of the company, along with information on its financial information (if available), product portfolio, recent developments and an informed future outlook. An estimate of the global installed capacity of bioreactors and fermenters for biologics manufacturing, based on information provided by various industry stakeholders in the public domain. It also features distribution of the available capacity on the basis of fabrication material (glass, stainless steel and single-use), source of cell culture (mammalian, microbial and others), reactor volume (less than 2,000 L, 2,000 to 5,000 L, 5,001 to 10,000 L and more than 10,000 L), type of manufacturer (in-house, hybrid and CMOs) and key geographical regions (North America, Europe, and Asia-Pacific and Rest of the World). A case study on the market landscape of bioprocess controllers and automation systems, providing information on scale of operation (laboratory, clinical, and commercial), key features (scalability / ease to use, visual data display, remote accessibility, built-in system control sensors, expansive I/O compatibility and provisions for alarms / alerts), compatibility with bioreactor system (stirred tank (glass), single-use bioreactor, stirred tank (steel), fermenter, rocking motion), type of bioprocess (batch, fed-batch and perfusion), and type of process controlled (cell cultivation and microbial fermentation). In addition, the chapter presents details of companies involved in the development of bioprocess control software, upstream and downstream controllers, including information on their respective year of establishment, company size, and location of headquarters. Stainless steel bioreactors hold a prominent share (~90%) of the current installed biomanufacturing capacity; majority of this is dedicated to the manufacturing of mammalian and microbial based therapeutics     The financial opportunity within the global bioreactors and fermenters market has been analyzed across the following segments: Type of Product Bioreactors Fermenters   Fabrication Material Glass Stainless Steel Single-use   Type of Bioprocess Batch and Fed-batch Continuous   Type of Biologic Antibodies Vaccines Cell Therapies Other Biologics   Key Geographical Regions North America Europe Asia-Pacific Rest of the World   Key Questions Answered Which are the top players in the global bioreactors and fermenters market? What is the global market size of bioreactors and fermenters? What are the factors driving the global bioreactors and fermenters market? Which region has the highest market share in global bioreactors and fermenters market? What are the leading market segments in global bioreactors and fermenters market? Which segment, in terms of bioreactor / fermenter capacity, accounts for the largest share in the global bioreactors and fermenters market? What is the growth rate (CAGR) in the global bioreactors and fermenters market? What are the upcoming trends in the global bioreactors and fermenters market?   To view more details on this report, click on the link https://www.rootsanalysis.com/reports/bioreactors-and-fermenters-market.html Learn from experts:  do you know about these emerging industry trends? At-home Self-testing: A Giant Leap Towards Transformation in Diagnostic Sector CAR-T Cell Therapies: Addressing Key Unmet Needs Across Various Oncological Indications   Learn from our recently published whitepaper: - Next Generation Biomanufacturing – The Upcoming Era of Digital Transformation   About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.   Learn more about Roots Analysis consulting services:  Roots Analysis Consulting - the preferred research partner for global firms   Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com  
Roots Analysis has done a detailed study on Gene Switch Market, 2023-2035, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.   Key Market Insights Presently, close to 50 gene switch platforms are being developed for various applications in adoptive cell therapies (ACT), including CAR-Ts, TCRs and gene therapies; majority of them are protein-based gene switches Various small molecules, including rimiducid, rapamycin and dasatinib, are being investigated to design safety switch for ACTs; management of treatment related toxicity has emerged as the key application of such platforms The current market landscape is fragmented, featuring the presence of both new entrants and established players; presently, majority of the gene switch platform developers are based in North America In pursuit of gaining a competitive edge, gene switch developers are presently undertaking several initiatives to expand their existing capabilities and augment respective product portfolios The growing interest in this domain is evident from the rise in licensing agreements over the last few years; majority of such deals were signed between players based in North America Several investors, having realized the opportunity within this domain, have invested over USD 3.5 billion across various funding rounds in the past five years Scientific articles being published for gene switch, reflect the growing research efforts of various industry and academic stakeholders; majority of the authors are affiliated to organizations based in North America More than 360 patents have been filed / granted by various stakeholders in order to protect the intellectual property generated within this field since 2014 Based on historical trends, we expect a steady growth in the licensing of gene switch platforms, in order to meet the growing demand for safe and effective gene therapies The gene switch market is expected to grow at a CAGR of 11.5% till 2035; the overall opportunity is anticipated to be well distributed across various segments, such as types of target therapies, application areas and key regions   Table of Contents   1. PREFACE 1.1. Introduction 1.2. Key Market Insights 1.3. Scope of the Report 1.4. Research Methodology 1.5. Key Questions Answered 1.6. Chapter Outlines   2. EXECUTIVE SUMMARY   3. INTRODUCTION 3.1. Chapter Overview 3.2. Emergence of Gene Switch 3.3. Applications of Gene Switch 3.4. Challenges Associated with Gene Switch 3.5. Concluding Remarks   4. MARKET LANDSCAPE 4.1. Chapter Overview 4.2. Gene Switch Platforms: Overall Market Landscape 4.3. Gene Switch Platform Developers: Developer Landscape   5. PRODUCT COMPETITIVENESS ANALYSIS 5.1. Chapter Overview 5.2. Assumptions and Key Parameters  5.3. Methodology  5.4. Product Competitiveness Analysis: Gene Switch Platforms   6. COMPANY PROFILES 6.1. Chapter Overview 6.2. aceRNA Technologies 6.2.1. Company Overview 6.2.2. Gene Switch Platform Portfolio 6.2.3. Recent Developments and Future Outlook 6.3. Autolus Therapeutics 6.4. Bellicum Pharmaceuticals 6.5. Cellectis 6.6. Kiromic BioPharma 6.7. panCELLa 6.8. Precigen 6.9. Sana Biotechnology 6.10. Sangamo Therapeutics   7. PARTNERSHIPS AND COLLABORATIONS 7.1. Chapter Overview 7.2. Partnership Models 7.3. Gene Switch Platforms: Partnerships and Collaborations   8. FUNDING AND INVESTMENT ANALYSIS 8.1. Chapter Overview 8.2. Type of Funding 8.3. Gene Switch Platforms: Funding and Investments Analysis   9. PUBLICATION ANALYSIS 9.1. Chapter Overview 9.2. Scope and Methodology 9.3. Gene Switch Platforms: Recent Publications   10. PATENT ANALYSIS 10.1. Chapter Overview 10.2. Scope and Methodology 10.3. Gene Switch Platforms: Patent Analysis 10.4. Gene Switch Platforms: Patent Benchmarking Analysis 10.5. Gene Switch Platforms: Patent Valuation 10.6. Leading Patents: Analysis by Number of Citations   11. BUSINESS MODEL ANALYSIS 11.1. Chapter Overview 11.2. Gene Switch Platform Developers: Business Model Analysis 11.3. Concluding Remarks   12. MARKET FORECAST AND OPPORTUNITY ANALYSIS 12.1. Chapter Overview 12.2. Key Assumptions and Forecast Methodology 12.3. Global Gene Switch Platform Market, 2023-2035   13. CONCLUDING REMARKS   14. APPENDIX 1: TABULATED DATA   15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS   To view more details on this report, click on the link https://www.rootsanalysis.com/reports/gene-switch-market.html Learn from experts:  do you know about these emerging industry trends? Long-Acting Drug Delivery: A Novel Pharmacological Strategy to Deliver Therapeutic Modalities Medical Device Coatings and Modification Technologies   Learn from our recently published whitepaper:- Next Generation Biomanufacturing – The Upcoming Era of Digital Transformation   About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.   Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com    
Roots Analysis has done a detailed study on “Cell and Gene Therapy CROs Market, 2022-2035”, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.   Key Market Insights More than 105 CROs claim to provide a wide range of preclinical and clinical services for the development of advanced therapy medicinal products. The current market landscape features the presence of established and emerging players, majority of the service providers offer research and analytical services for both cell and gene therapies at different scales of operation. Around 1,330 cell and gene therapy focused clinical trials have been registered across the globe; most of the trials are focused on evaluating therapy candidates for the treatment of various oncological indications In pursuit of a competitive edge and to eventually establish themselves as one-stop shops, stakeholders have actively entered into mutually beneficial partnerships We expect industry stakeholders to continue to forge strategic alliances with niche / specialized players engaged in this domain to further augment their respective product offerings Our proprietary analysis highlights several potential acquisition partners for cell and gene therapy service providers across different geographies Our proprietary total cost of ownership model provides an informed estimate of direct and indirect expenses for setting up a contract research facility in different regions, over a span of 20 years The market is expected to grow at a CAGR of over 21% in the coming decade; the opportunity is likely to be well distributed across areas of expertise, therapeutic areas, scales of operation and key geographical regions   Table of Contents 1.                     PREFACE 1.1.                  Scope of the Report 1.2.                  Market Segmentation 1.3.                  Research Methodology 1.4.                  Key Questions Answered 1.5.                  Chapter Outlines   2.                     EXECUTIVE SUMMARY 2.1.                  Chapter Overview   3.                     INTRODUCTION 3.1.                  Chapter Overview 3.2.                  Overview of Contract Research Organizations (CROs) 3.3.                  Type of Services Offered by CROs 3.4.                  Classification of CROs 3.5.                  Role of CROs in Development of Advanced Therapy Medicinal Products (ATMPs) 3.6.                  Advantages of Outsourcing Operations to CROs 3.7.                  Risks Associated with Outsourcing to CROs 3.8.                  Future Perspectives   4.                     GUIDE TO OUTSOURCING 4.1.                  Chapter Overview 4.2.                  Outsourcing Cell and Gene Therapy Research  4.3.                  Guiding Models of Outsourcing 4.4.                  Selecting an Appropriate Outsourcing Model 4.5.                  Selecting a CRO Partner 4.6.                  Role of CROs in Drug Development 4.7.                  Concluding Remarks   5.                     MARKET LANDSCAPE 5.1.                  Chapter Overview 5.2.                  Cell and Gene Therapy CROs: Overall Market Landscape   6.                     COMPANY PROFILES 6.1.                  Chapter Overview 6.2.                  Players based in North America 6.2.1.               Altasciences 6.2.1.1.             Company Overview 6.2.1.2.            Service Portfolio 6.2.1.3.            Recent Developments and Future Outlook 6.2.2.               Allucent (Formerly Known as CATO SMS) 6.2.3.               Charles River Laboratories 6.2.4.               Creative Biolabs 6.2.5.               IQVIA 6.2.6.               Medpace 6.2.7.               PPD 6.2.8.               Precision for Medicine 6.2.9.               QPS   6.3.                  Players based in Europe 6.3.2.               Evotec 6.3.3.               ICON 6.3.4.               Syneos Health   6.4.                  Players based in Asia-Pacific 6.4.1.               CMIC Group 6.4.2.               Labcorp   7.                     COMPETITIVE BENCHMARKING 7.1.                  Chapter Overview 7.2.                  Assumptions and Key Methodology 7.3.                  Competitive Benchmarking by Region 7.4.                  Concluding Remarks   8.                     PARTNERSHIPS AND COLLABORATIONS 8.1.                  Chapter Overview 8.2.                  Partnership Models 8.3.                  Cell and Gene Therapy CROs: Partnerships and Collaborations   9.                    MERGERS AND ACQUISITIONS 9.1.                 Chapter Overview 9.2.                 Merger and Acquisition Models 9.3.                 Cell and Gene Therapy CROs: Mergers and Acquisitions   10.                   KEY ACQUISITION TARGETS 10.1.                Chapter Overview 10.2.                Scoring Criteria and Key Assumptions 10.3.                Scope and Methodology 10.4.                Potential Strategic Acquisition Targets Amongst Small Players 10.5.                Potential Strategic Acquisition Targets Amongst Mid-sized Players   11.                   LIKELY PARTNER ANALYSIS FOR CELL THERAPY CROs 11.1.                Chapter Overview 11.2.                Scoring Criteria and Key Assumptions 11.3.                Scope and Methodology 11.4.                Key Potential Strategic Partners for Cell Therapy CROs   12.                   LIKELY PARTNER ANALYSIS FOR GENE THERAPY CROs 12.1.                Chapter Overview 12.2.                Scoring Criteria and Key Assumptions 12.3.                Scope and Methodology 12.4.                Key Potential Strategic Partners for Gene Therapy CROs   13.                   CLINICAL TRIAL ANALYSIS 13.1.                Chapter Overview 13.2.                Scope and Methodology 13.3.                Cell Therapies: Analysis by Number of Clinical Trials 13.4.                Cell Therapies: Analysis by Enrolled Patient Population   13.5.                Gene Therapies: Analysis by Number of Clinical Trials 13.6.                Gene Therapies: Analysis by Enrolled Patient Population                           14.                   TOTAL COST OF OWNERSHIP FOR CELL AND GENE THERAPY CONTRACT             RESEARCH ORGANIZATIONS 14.1                 Chapter Overview 14.2.                Key Parameters 14.3.                Assumptions and Methodology 14.4                 Sample dataset for the estimation of total cost of ownership                         15.                   MARKET FORECAST AND OPPORTUNITY ANALYSIS 15.1.                Chapter Overview 15.2.                Key Assumptions and Methodology   15.3.                Global Cell and Gene Therapy CROs Market, 2022-2035   16.                   SWOT ANALYSIS 16.1.                Chapter Overview 16.2.                Strengths 16.3.                Weaknesses 16.4.                Opportunities 16.5.                Threats 16.6.                Comparison of SWOT Factors   17.                   CONCLUSION 17.1.                Chapter Overview   18.                   INTERVIEW AND SURVEY TRANSCRIPTS 18.1.                Chapter Overview 18.2.                CATO SMS 18.3.                Changhai Hospital, Second Military Medical University 18.4.                University of Colorado   16.                   APPENDIX 1: TABULATED DATA   17.                   APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS   To view more details on this report, click on the link: https://www.rootsanalysis.com/reports/view_document/cell-and-gene-therapy-cros-market/230.html Learn from experts:  do you know about these emerging industry trends? Key Trends in Non-Viral Transfection Market Deep Learning-based Interoperability: Advanced Neural Networks Mimicking the Human Brain   Learn from our recently published whitepaper: - Next Generation Biomanufacturing – The Upcoming Era of Digital Transformation   About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.   Learn more about Roots Analysis consulting services:  Roots Analysis Consulting - the preferred research partner for global firms   Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com  
Roots Analysis has done a detailed study on Cell Therapy Media, Kits, Reagents and Surfaces Market, 2023-2035, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.   Key Market Insights Leveraging their expertise, over 450 types of kits, media, reagents and extracellular matrices have been manufactured by consumable providers for research and therapeutic purposes The market features the presence of more than 80 firms across the globe; majority of these stakeholders are emerging players based in North America A larger proportion of the kits available in the cell therapy domain comprise of different types of reagents; of these, 60% are intended for use with stem cell therapies and nearly 80% are stored in refrigerated conditions Media developers are offering products for a broad range of cell therapies; nearly 90% of such players are providing media in the volume range of 100 to 500 ml Predominantly, the cell therapy reagents are intended to be used at discovery scale of operation for a wide spectrum of functions, including cell expansion and proliferation The market landscape of matrices, which typically have a shelf life of 1 to 1.5 years, is well distributed in terms of type of ECM coating and type of formulation In pursuit of gaining a competitive edge, cell therapy consumable providers are upgrading their existing technologies and expanding their product portfolios Many companies have undertaken strategic initiatives, including partnerships, acquisitions and expansions, to augment their existing capabilities We expect industry stakeholders to continue to forge strategic alliances with niche / specialized players engaged in this domain to further augment their respective product offerings Over the years, stakeholders within this industry have established strong brand positions by undertaking a range of initiatives to further advance the development of raw materials for cell therapies Cost is a key determinant for the adoption of consumables in a cell therapy manufacturing process; the pricing strategy matrix is likely to assist players in evaluating the competitive market prices for their products In 2035, the commercial scale of operation is likely to account for 75% of the total demand for cell therapy surface; this is attributed to the expected surge in the anticipated approvals of multiple cell therapies A paradigm shift from animal-based to animal component free formulations, combined with stringent regulatory guidelines, is likely to drive the growth of the cell therapy media market at an annualized rate of 12% The projected future opportunity for cell therapy consumable providers is expected to be well distributed across different types of end-users and key geographical regions   Table of Contents 1.                     PREFACE 1.1.                  Introduction 1.2.                  Key Market Insights   1.3.                  Scope of the Report 1.4.                  Research Methodology 1.5.                  Frequently Asked Questions 1.6.                  Chapter Outlines   2.                     EXECUTIVE SUMMARY   3.                     INTRODUCTION 3.1.                  Context and Background 3.2.                  Introduction to Cell Therapies 3.3.                  Comparison of Cell Therapies with Other Biopharmaceuticals 3.4.                  Classification of Cell Therapy Products 3.5.                  Overview of Cell Therapy Development and Manufacturing 3.6.                  Role of Raw Materials in Cell Therapy Development and Manufacturing 3.7.                  Types of Cell Therapy Consumables 3.8.                  Key Challenges Associated with Manufacturing of Cell Therapy Consumables 3.9.                  Future Perspectives   4.                     MARKET LANDSCAPE 4.1.                  Chapter Overview 4.2.                  List of Cell Therapy Kit Providers 4.3.                  List of Cell Therapy Media Providers 4.4.                  List of Cell Therapy Reagent Providers 4.5.                  List of Cell Therapy Extracellular Matrix Providers   5.                     COMPANY COMPETITIVENESS ANALYSIS 5.1.                  Chapter Overview 5.2.                  Key Assumptions and Parameters 5.3.                  Methodology 5.4.                  Cell Therapy Consumables Providers: Company Competitiveness Analysis 5.5.                  Cell Therapy Kits Providers 5.6.                  Cell Therapy Media Providers 5.7.                  Cell Therapy Reagent Providers 5.8.                  Cell Therapy Extracellular Matrix Providers   6.                     BRAND POSITIONING OF KEY INDUSTRY PLAYERS 6.1.                  Chapter Overview 6.2.                  Scope and Methodology 6.3.                  Brand Positioning: STEMCELL Technologies 6.4.                  Brand Positioning: Miltenyi Biotec 6.5.                  Brand Positioning: Thermo Fisher Scientific 6.6.                  Brand Positioning: Takara Bio 6.7.                  Brand Positioning: GeminiBio   7.                     COMPANY PROFILES 7.1.                  Chapter Overview   7.2.                  STEMCELL Technologies 7.2.1.               Company Overview 7.2.2.               Product Portfolio 7.2.3.               Recent Developments and Future Outlook 7.3.                  Miltenyi Biotec 7.4.                  Thermo Fisher Scientific 7.5.                  Bio-Techne 7.6.                  Irvine Scientific 7.7.                  Lonza 7.8.                  Sartorius 7.9.                  BD Biosciences 7.10.                Corning 7.11.                CellGenix   8.                     RECENT DEVELOPMENTS AND INITIATIVES 8.1.                  Chapter Overview 8.2.                  Partnership Models 8.3.                  Cell Therapy Consumables: Partnerships and Collaborations 8.4.                  Cell Therapy Consumables: Mergers and Acquisitions 8.5.                  Cell Therapy Consumables: Recent Expansions   9.                     LIKELY PARTNER ANALYSIS FOR CELL THERAPY CONSUMABLE PROVIDERS 9.1.                  Chapter Overview 9.2.                  Scoring Criteria and Key Assumptions 9.3.                  Scope and Methodology 9.4.                  Key Potential Strategic Partners for Cell Therapy Consumable Providers   10.                   ROOTS ANALYSIS PRICING STRATEGY 10.1.                Chapter Overview 10.2.                Roots Analysis Framework   11.                   DEMAND ANALYSIS 11.1.                Chapter Overview 11.2.                Scope and Methodology 11.3.                Global Demand for Cell Therapy Consumables 11.4.                Analysis by Scale of Operation 11.5.                Analysis by Geography             12.                   MARKET FORECAST AND OPPORTUNITY ANALYSIS 12.1.                Chapter Overview 12.2.                Key Assumptions and Methodology 12.3.                Global Cell Therapy Consumables Market, 2023-2035 12.4.                Cell Therapy Consumables Market: Analysis by Type of Product 12.5.                Cell Therapy Consumables Market: Analysis by Type of Cell Therapy 12.6.                Cell Therapy Consumables Market: Analysis by Scale of Operation 12.7.                Cell Therapy Consumables Market: Analysis by Type of End-User 12.8.                Cell Therapy Consumables Market: Analysis by Geography   13.                   UPCOMING TRENDS AND FUTURE GROWTH OPPORTUNITIES 13.1.                Chapter Overview 13.2.                Emerging Trends Related to Cell Culture Media 13.3.               Automation of Cell Therapy Manufacturing Processes 13.4.                Single Use Systems and Technologies in Cell Therapy Manufacturing   14.                  CONCLUDING REMARKS   15.                   INTERVIEW TRANSCRIPTS   16.                   APPENDIX I: TABULATED DATA   17.                   APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS   To view more details on this report, click on the link https://www.rootsanalysis.com/reports/cell-therapy-consumables-market.html   Learn from experts:  do you know about these emerging industry trends? Unlocking the Potential of Digital Twins in Healthcare: Benefits, Challenges and Opportunities   Learn from our recently published whitepaper: - Next Generation Biomanufacturing – The Upcoming Era of Digital Transformation   About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.   Learn more about Roots Analysis consulting services:  Roots Analysis Consulting - the preferred research partner for global firms   Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com